During a Congressional hearing, US pharmaceutical industry intermediaries defended their roles in the healthcare system. Committee members accused these intermediaries of pushing patients toward expensive treatments despite the availability of lower-cost options. A House Committee on Oversight and Accountability report released earlier that day provided evidence suggesting that pharmacy benefit managers (PBMs) compel drugmakers to pay rebates for placing branded…